The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).
Analysts’ Views on Global Hematopoietic Stem Cell Transplantation (HSCT) Market:
The increasing investment and funding by key market players is expected to drive market growth over the forecast period. For instance, in November 2021, Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, announced it had secured an US$87 million in Series A financing led by Syncona Ltd., an investment company. This financing supports the development of the company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells.
Figure 1. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Transplant Type, 2023
To learn more about this report, Request sample copy
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Drivers
Figure 2. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Region, 2023
To learn more about this report, Request sample copy
Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global hematopoietic stem cell transplantation (HSCT) market is expected to witness significant growth in the coming years due to increasing inorganic growth strategies such as mergers to expand their product portfolio in North America region. For instance, in May 2021, Jasper Therapeutics, Inc., a U.S. based biotechnology company focused on hematopoietic cell transplant therapies, announced the merger with Amplitude Healthcare Acquisition Corporation, a private life science company, to provide significant capital to accelerate the development of our two innovative programs: Jasper’s first-in-class clinical-stage anti-CD117 antibody transplant conditioning agent and, in parallel, our groundbreaking research stage Engineered Hematopoietic Stem Cell platform.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
However, the COVID-19 pandemic had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market, owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an American College of Surgeons (ACS) 2021 report, the nature of surgery and anesthesia practices changed during the COVID-19 pandemic as the most elective and non-urgent cases were postponed.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation:
The global hematopoietic stem cell transplantation (HSCT) market report is segmented into transplant type, indication, application, end user and region.
Among all the segmentation, the transplant type segment is expected to dominate the market over the forecast period, and this is attributed to increasing inorganic growth strategies such as acquisition by key market players to expand their product portfolio. For instance, in September 2021, Sanofi, a pharmaceutical company, announced the acquisitions of Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops, and markets transformative therapies. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and immediately add Rezurock (belumosudil) to its transplant portfolio. Rezurock is a first-in-class treatment for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years of age and older who have failed at least two prior lines of systemic therapy.
Hematopoietic Stem Cell Transplantation (HSCT) Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 2.88 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 11.2% | 2030 Value Projection: | US$ 6.05 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Cross Sectional Analysis:
The increasing inorganic growth strategies, such as acquisitions by key market players to expand their product portfolio, are expected to drive market growth in North America region over the forecast period. For instance, in June 2021, Avalon Globocare Corp., a commercial-stage company, announced the acquisition of Hebei Senlang Biotechnology Co. Ltd., a cell therapy company, and developed a robust pipeline that includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδT cell therapy candidates targeting hematologic malignancies and solid tumors.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Developments
On June 19, 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.
On January 23, 2023, Researchers at Children's Hospital of Philadelphia (CHOP) developed a custom-built application to automate the determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and, at the same time, substantially improves the accuracy of reported hematopoietic cell transplant engraftments.
On January 4, 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).
In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.
Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Trends
Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Restraint
The company operating in market should follows the rules and regulation during development process of product to maintain the quality of product
Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Key Players
Major players operating in the global hematopoietic stem cell transplantation (HSCT) market include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
Definition: Hematopoietic stem cell transplantation (HSCT) is a treatment for some types of cancer and other diseases. Stem cells can come from the blood or bone marrow. The Food and Drug Administration (FDA)Trusted Source has approved the use of stem cell transplants to treat multiple myeloma, leukemia, some lymphomas, and others. Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). Pediatric hematopoietic stem cell transplantation involves the infusion of blood stem cells into a patient to reconstitute the blood system.
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients